At the end of last year, the total scale of funds managed by the new 100 billion fund managers in Glen reached 65.438+065.438+0039 billion yuan, which has exceeded the volume of 65.438+006.5438+09 billion yuan in Zhang Kun in the same period. Since the beginning of this year, the pharmaceutical sector market has continued to be sluggish, and leading pharmaceutical companies have been "thunderstruck" one after another. Therefore, the income of these two medical fund products is not very good.

Take Gulen's representative work, China-Europe Medical Health, for example. The top ten stocks: Wuxi PharmaTech, Aier Ophthalmology, Gloria, Tiger Medicine, Kang Longhua Cheng, Mindray Medical, Tongce Medical, Pien Tze Huang, Kyushu Pharmaceutical, and Boteng, all showed unsatisfactory performance after the Spring Festival, with a drop of more than 20%.